In recent years, anti-vascular endothelial growth factor (VEGF) agents have been widely used as an alternative to treat severe ROP, knowing that they can prevent or reduce pathological neovascularization and maintain retinal integrity. This evidence concerns the gene VEGFA and retinopathy of prematurity.